Search Results - "Baird, John H."

Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy by Good, Zinaida, Spiegel, Jay Y., Sahaf, Bita, Malipatlolla, Meena B., Ehlinger, Zach J., Kurra, Sreevidya, Desai, Moksha H., Reynolds, Warren D., Wong Lin, Anita, Vandris, Panayiotis, Wu, Fang, Prabhu, Snehit, Hamilton, Mark P., Tamaresis, John S., Hanson, Paul J., Patel, Shabnum, Feldman, Steven A., Frank, Matthew J., Baird, John H., Muffly, Lori, Claire, Gursharan K., Craig, Juliana, Kong, Katherine A., Wagh, Dhananjay, Coller, John, Bendall, Sean C., Tibshirani, Robert J., Plevritis, Sylvia K., Miklos, David B., Mackall, Crystal L.

“…Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen receptor (CAR) T cell therapies targeting CD19 experience disease…”
Get full text

Inhibiting Adipose Tissue Lipogenesis Reprograms Thermogenesis and PPARγ Activation to Decrease Diet-Induced Obesity by Lodhi, Irfan J., Yin, Li, Jensen-Urstad, Anne P.L., Funai, Katsuhiko, Coleman, Trey, Baird, John H., El Ramahi, Meral K., Razani, Babak, Song, Haowei, Fu-Hsu, Fong, Turk, John, Semenkovich, Clay F.

“…De novo lipogenesis in adipocytes, especially with high fat feeding, is poorly understood. We demonstrate that an adipocyte lipogenic pathway encompassing…”
Get full text

Simultaneous targeting of B-cell malignancies and human immunodeficiency virus with bispecific chimeric antigen receptor T cells by Urak, Ryan, Pahlavanneshan, Saghar, Gittins, Brenna, Nakamura, Ryotaro, Zaia, John A, Baird, John H, Clark, Mary C, Forman, Stephen J, Wang, Xiuli

Get full text

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma by Baird, John H., Epstein, David J., Tamaresis, John S., Ehlinger, Zachary, Spiegel, Jay Y., Craig, Juliana, Claire, Gursharan K., Frank, Matthew J., Muffly, Lori, Shiraz, Parveen, Meyer, Everett, Arai, Sally, Brown, Janice (Wes), Johnston, Laura, Lowsky, Robert, Negrin, Robert S., Rezvani, Andrew R., Weng, Wen-Kai, Latchford, Theresa, Sahaf, Bita, Mackall, Crystal L., Miklos, David B., Sidana, Surbhi

“…Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has significantly improved outcomes in the treatment of refractory or relapsed large B-cell…”
Get full text

Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis by Baird, John H., Gotlib, Jason

“…Purpose of Review We discuss recent developments in the treatment of advanced systemic mastocytosis (advSM) with inhibitors of the KIT receptor tyrosine…”
Get full text

A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis by Gotlib, Jason, Baird, John H., George, Tracy I., Langford, Cheryl, Reyes, Isabel, Abuel, Justin, Perkins, Cecelia, Schroeder, Kurt, Bose, Prithviraj, Verstovsek, Srdan

“…There is an unmet need for effective therapies for advanced systemic mastocytosis (advSM). CD30 is expressed on the surface of neoplastic mast cells (MC) in…”
Get full text

A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist by Ong, Shin Yeu, Baird, John H.

“…Chimeric antigen receptor (CAR) T-cell therapy is an innovative treatment approach that has shown remarkable efficacy against several hematologic malignancies…”
Get full text

An Unusual Cause of Epistaxis: Paranasal Sinus Myeloid Sarcoma by Dewan, Karuna, Shires, Courtney B., Baird, John H.

“…We report a case of a 65-year-old female who presented with right-sided headaches, blurring of vision in the right eye, cold-induced epistaxis, and facial…”
Get full text

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial by Spiegel, Jay Y., Patel, Shabnum, Muffly, Lori, Hossain, Nasheed M., Oak, Jean, Baird, John H., Frank, Matthew J., Shiraz, Parveen, Sahaf, Bita, Craig, Juliana, Iglesias, Maria, Younes, Sheren, Natkunam, Yasodha, Ozawa, Michael G., Yang, Eric, Tamaresis, John, Chinnasamy, Harshini, Ehlinger, Zach, Reynolds, Warren, Lynn, Rachel, Rotiroti, Maria Caterina, Gkitsas, Nikolaos, Arai, Sally, Johnston, Laura, Lowsky, Robert, Majzner, Robbie G., Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Sidana, Surbhi, Shizuru, Judith, Weng, Wen-Kai, Mullins, Chelsea, Jacob, Allison, Kirsch, Ilan, Bazzano, Magali, Zhou, Jing, Mackay, Sean, Bornheimer, Scott J., Schultz, Liora, Ramakrishna, Sneha, Davis, Kara L., Kong, Katherine A., Shah, Nirali N., Qin, Haiying, Fry, Terry, Feldman, Steven, Mackall, Crystal L., Miklos, David B.

“…Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease…”
Get full text

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas by Sworder, Brian J., Kurtz, David M., Alig, Stefan K., Frank, Matthew J., Shukla, Navika, Garofalo, Andrea, Macaulay, Charles W., Shahrokh Esfahani, Mohammad, Olsen, Mari N., Hamilton, James, Hosoya, Hitomi, Hamilton, Mark, Spiegel, Jay Y., Baird, John H., Sugio, Takeshi, Carleton, Mia, Craig, Alexander F.M., Younes, Sheren F., Sahaf, Bita, Sheybani, Natasha D., Schroers-Martin, Joseph G., Liu, Chih Long, Oak, Jean S., Jin, Michael C., Beygi, Sara, Hüttmann, Andreas, Hanoun, Christine, Dührsen, Ulrich, Westin, Jason R., Khodadoust, Michael S., Natkunam, Yasodha, Majzner, Robbie G., Mackall, Crystal L., Diehn, Maximilian, Miklos, David B., Alizadeh, Ash A.

“…Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19 chimeric antigen receptor (CAR19) T cells relapse. To characterize…”
Get full text

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma by Baird, John H., Frank, Matthew J., Craig, Juliana, Patel, Shabnum, Spiegel, Jay Y., Sahaf, Bita, Oak, Jean S., Younes, Sheren F., Ozawa, Michael G., Yang, Eric, Natkunam, Yasodha, Tamaresis, John, Ehlinger, Zachary, Reynolds, Warren D., Arai, Sally, Johnston, Laura, Lowsky, Robert, Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Sidana, Surbhi, Weng, Wen-Kai, Davis, Kara L., Ramakrishna, Sneha, Schultz, Liora, Mullins, Chelsea, Jacob, Allison, Kirsch, Ilan, Feldman, Steven A., Mackall, Crystal L., Miklos, David B., Muffly, Lori

“…The prognosis of patients with large B-cell lymphoma (LBCL) that progresses after treatment with chimeric antigen receptor (CAR) T-cell therapy targeting CD19…”
Get full text

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma by Godfrey, James K., Gao, Lei, Shouse, Geoffrey, Song, Joo Y., Pak, Stacy, Lee, Brian, Chen, Bihong T., Kallam, Avyakta, Baird, John H., Marcucci, Guido, Ghoda, Lucy, Vauleon, Stephanie, Danilov, Alexey V., Herrera, Alex F., Kwak, Larry W., Budde, Lihua E.

“…Although CD20×CD3 bispecific antibodies are effective against systemic B-cell lymphomas, their efficacy in central nervous system (CNS) lymphoma is unknown…”
Get full text

Real‐world experience of axicabtagene ciloleucel, a CD19‐directed CAR T‐cell therapy, in the second‐line treatment of early relapsed or primary refractory large B‐cell lymphoma by Othman, Tamer, Baird, John H., Pak, Stacy, Mei, Matthew, Herrera, Alex F., Mansour, Joshua, Shouse, Geoffrey, Sahebi, Firoozeh, Spielberger, Ricardo, Cai, Ji‐Lian, Farol, Leonardo, Godfrey, James, Kallam, Avyakta, Phillips, Tycel, Popplewell, Leslie, Siddiqi, Tanya, Forman, Stephen, Budde, Lihua E.

Get full text

Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma by Ong, Shin Yeu, Pak, Stacy, Mei, Matthew, Wang, Yan, Popplewell, Leslie, Baird, John H., Herrera, Alex F., Shouse, Geoffrey, Nikolaenko, Liana, Zain, Jasmine, Godfrey, James, Htut, Myo, Aribi, Ahmed, Spielberger, Ricardo, Mansour, Joshua, Forman, Stephen J., Palmer, Joycelynne, Budde, Lihua E.

“…Fludarabine/cyclophosphamide (Flu/Cy) is established for lymphodepletion (LD) prior to standard‐of‐care CAR T‐cell therapy for lymphoma. There is ongoing need…”
Get full text

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis by Rainone, Michael, Ngo, Dat, Baird, John H., Budde, L. Elizabeth, Htut, Myo, Aldoss, Ibrahim, Pullarkat, Vinod

Get full text

Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma by Ladbury, Colton, Dandapani, Savita, Hao, Claire, Fabros, Mildred, Amini, Arya, Sampath, Sagus, Glaser, Scott, Sokolov, Karen, Yeh, Jekwon, Baird, John H, Thiruvengadam, Swetha Kambhampati, Herrera, Alex, Mei, Matthew, Nikolaenko, Liana, Shouse, Geoffrey, Budde, Lihua E

“…Bridging therapy (BT) with systemic therapy (ST), radiation therapy (RT), or combined-modality therapy (CMT) is increasingly being utilized prior to chimeric…”
Get full text

Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in sickle cell disease by Vuren, Annelies J., Minniti, Caterina P., Mendelsohn, Laurel, Baird, John H., Kato, Gregory J., Beers, Eduard J.

Get full text

COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies by Harris, Courtney E, Vijenthira, Abi, Ong, Shin Yeu, Baden, Lindsey Robert, Hicks, Lisa K, Baird, John H

“…COVID-19 and our armamentarium of strategies to combat it have evolved dramatically since the virus first emerged in late 2019. Vaccination remains the primary…”
Get more information

Voriconazole‐induced periostitis after allogeneic stem cell transplantation by Baird, John H., Birnbaum, Belinda K., Porter, David L., Frey, Noelle V.

Get full text

Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma by Nie, Esther H., Su, Yi-Jiun, Baird, John H., Agarwal, Neha, Bharadwaj, Sushma, Weng, Wen-Kai, Smith, Melody, Dahiya, Saurabh, Han, May H., Dunn, Jeffrey E., Kipp, Lucas B., Miklos, David B., Scott, Brian J., Frank, Matthew J.

“…•In patients with MCL receiving brexucabtagene autoleucel complicated by severe ICANS, 86% of patients demonstrated acute brain MRI findings.•Severe…”
Get full text